NEFL and Guillain-Barre syndrome: Inhibition of C1q factor with the monoclonal antibody ANX005 in GBS has shown preliminary evidence of efficacy (NfL reduction and improvement of GBS disability score in the first weeks after treatment) [90] and remains under evaluation.